Oncology & Haematology Conference Handbook

Transcription

Oncology & Haematology
Conference 2015
CONFERENCE
HANDBOOK
Friday 20 and Saturday 21 March 2015
Ko Awatea, Middlemore Hospital Campus, Auckland
Proudly supported by:
ACKNOWLEDGMENTS
The Organising Committee would like to extend their gratitude to all the sponsors and
exhibitors without whom this conference would not have been possible. Please take
the time to visit all the exhibition stands to say hello, see what’s new, and complete the
quiz competition to win an iPad Mini.
In particular we acknowledge the following sponsors:
Platinum
Gold
International
Speaker
Bronze
2
Oncology & Haematology Conference 2015
CONTENTS
Welcome4
General Information
5
Social Programme
7
Keynote Speaker
8
Invited Speakers
9
Programme
Friday
11
Saturday
14
Abstracts
Oral
16
Exhibition Floor Plan
36
Exhibitor Directory
37
Exhibitor Information 38
Middlemore Campus Map
Inside Back Page
Venue Floor Plan Back page
ORGANISING COMMITTEE
Convenor
Angela Knox, Clinical Nurse Manager, Haematology Day Ward, Middlemore Hospital
Committee:
Ella Liang, Nurse, Haematology Day Ward, Middlemore Hospital
Janene Lawrence, Clinical Nurse Manager, Counties Manukau DHB
Kathryn McWatt, Nurse Educator, Counties Manukau Health
Hannah Milner, Nurse, Haematology Day Ward, Middlemore Hospital
Anne-Marie Wilkins, Lead Cancer Nurse Coordinator, Middlemore Hospital
CONFERENCE ORGANISERS
ForumPoint2 Limited
PO Box 1008, WMC
Hamilton 3240
Contact: Paula Armstrong | Project Manager
T: +64 7 838 1098
E: Paula@fp2.co.nz
www.fp2.co.nz
3
WELCOME
On behalf of the organising committee, we warmly welcome you to
Ko Awatea, Counties Manuaku and the 2015 NZNO Cancer Nurses:
Oncology and Haematology Conference. We are sure you will enjoy the
range of high quality national and international speakers throughout this
programme. It is with great regret that Shelly Dolan is unable to be with
us in person, but luckily through technology, she will be able to present
and be available for an interactive session on Saturday.
I would also encourage you to make the most of visiting the exhibitors,
without their support, conferences such as this would not be possible.
I hope you enjoy yourself, both at the social event and also in
networking and catching up with old friends and making new ones.
ORGANISING COMMITTEE
Convenor
Angela Knox
4
GENERAL INFORMATION
REGISTRATION AND INFORMATION DESK
The registration desk is staffed by Paula and Claire who welcome your enquiries on any
conference detail or local information. The desk will be open on Friday 20 March from
8.00am.
Useful Telephone Numbers
Registration Desk Staff:
Paula
Tel: 027 649 2081
Ko Awatea
Holiday Inn Auckland Airport
Auckland Coop Taxis
Super Shuttle
Tel: (09) 267 0044
Tel: 0800 080 236 or (09) 275 1059
Tel: (09) 300 3000
Tel: 0800 748 885 or (09) 522 5100 from a mobile
ATTENDEE LIST
There is a list of attendees in your conference bag.
CERTIFICATE OF ATTENDANCE
A certificate of attendance can be found inside your registration envelope.
EVALUATION
An online evaluation survey will be emailed to attendees after the conference. We
welcome your feedback and would be grateful for a few minutes of your time to
complete this.
INSURANCE
Registration fees do not include personal, travel or health insurance of any
kind. Neither the NZNO Cancer Nurses College nor ForumPoint2 Limited takes
responsibility for delegates failing to take out adequate insurance cover.
INTERNET ACCESS
Complimentary Wifi access is available to conference delegates; Login information will
be posted on the main lecture room screen and by the conference registration desk.
The password will change daily.
If you have difficulty logging on, please see the ForumPoint2 team at the conference
registration desk.
MESSAGES
For anyone wishing to leave you a message during conference hours, please ask them
to use the following number for the registration desk. Registration desk: 027 649 2081
MOBILE PHONES
During conference sessions mobile phones must be set to silent or vibrate. We ask that
mobile phones are not used while sessions are in progress.
5
NAME BADGES
All conference attendees and industry representatives are asked to wear their name
badges at all times during the conference and social functions. It is your official
entrance pass to the sessions, catering and exhibition.
Please return your name badge and plastic registration envelope to the conference
registration desk at the end of the conference for recycling.
PARKING
Paid parking is available in Car Park 4 via Gate 1 on Hospital Road. There is a limited
amount of carparks in this area and is based on a first in scenario.
PRESENTERS’ INFORMATION
Oral presentations
Presentations are being loaded in the room in which the speaker is presenting. Please go
to load and check your presentation as soon as possible after your arrival at the conference.
If you plan to present using your own laptop please speak to the technician on your
arrival at the meeting.
Please be in the conference room where you are presenting ten minutes before the
start of the session to check your presentation, familiarise yourself with the AV set-up
and meet the session chair.
POWERPOINT PRESENTATIONS
Where presenters have approved, PowerPoint presentations will be saved and posted
to www.nzno.org.nz/groups/colleges/cancer_nurses_college following the conference.
SESSIONS CHAIRS
Ten minutes prior to your session commencing, please be in the conference room to meet
the presenters. Please ensure each session starts and finishes at the advertised time.
SPECIAL DIETS
If you have advised us of any special dietary requirements on your registration form
these have been notified to the caterers.
There will be a “pre-ordered special dietary requirement” table located in Room 103 in
the catering area for notified special diets. Please make yourself known to the catering
staff at the conference dinner. If you have difficultly locating your appropriate meal
options please contact the ForumPoint2 team at the conference registration desk.
WATER REFILL STATION
A kitchen area is located behind Wishbone café, there is a filtered water tap here for
you to refill your water bottles.
DISCLAIMER OF LIABILITY
Whilst we have endeavoured to ensure that information on the conference website and printed
material is accurate, details may be subject to change without notice. Any corrections or
amendments will be notified as soon as possible. In the event of industrial disruptions, or service
provider failures, the NZNO Cancer Nurses College nor ForumPoint2 Limited will not accept any
responsibility for losses incurred by attendees or their partners.
Although care has been taken to ensure accuracy, the conference committee does not accept
liability for any errors in published abstracts.
6
Bus transfer schedule
There will be two buses transferring delegates at the times stated below. The buses
will depart, once full, promptly at the times stated below. Please ensure you are in the
departure location at least five minutes prior to the time stated below.
Date
Departure time
From
To
Friday 20 March
7.45am
Holiday Inn Auckland
Airport
Ko Awatea,
Middlemore
Hospital Campus
Friday 20 March
4.45pm
Ko Awatea, Middlemore
Hospital Campus
Holiday Inn
Auckland Airport
Saturday 21 March 6.45am
Holiday Inn Auckland
Airport
Ko Awatea,
Middlemore
Hospital Campus
Saturday 21 March 2.45pm
Ko Awatea, Middlemore
Hospital Campus
Holiday Inn
Auckland Airport
SOCIAL PROGRAMME
Conference Dinner
Friday 20 March 2015
7.00pm to midnight
Venue: Jean Batten Ballroom,
Holiday Inn Auckland Airport,
Auckland
Dress/Theme: The Roaring 20’s
Your ticket includes your
meal, a drink on arrival and
entertainment. A cash bar will
be operating, please bring
cash, eftpos or credit card to
purchase additional beverages.
Entertainment:
Get ready to dance the evening away to the fabulous sounds of The Shy and Retiring
Company.
Important
Please take your ticket with you to the dinner (inside your name badge pocket), these
will be collected. If you have a ticket for the dinner, but will no longer be attending,
please advise the ForumPoint2 team at the conference registration desk.
7
KEYNOTE SPEAKERS
Dr Shelley Dolan
Shelley worked in Critical Care until 1990 exploring specialities
such as Trauma, Burns and Plastics, Coronary Care, Children’s ITU,
neonatal ITU and General ITU in major units across the UK. Then
in 1990, Shelley made a move to the critical care of the cancer
patient. In 2000 Shelley was appointed as the Royal Marsden
Nurse Consultant for Cancer: Critical Care. Finally, in June 2007
Shelley was delighted to be appointed as Chief Nurse of The Royal
Marsden NHS Foundation Trust. As Chief Nurse, Shelley leads the
nursing professionals at the Trust and is also the Board lead for clinical governance
across all professional groups. In December 2012, Shelley was appointed as Clinical
Director for The London Cancer Alliance an NHS body seeking to raise safety and
quality for patients with cancer in 17 hospitals across London. Shelley’s first degree was
in English, in 1996 she completed her MSc in cancer care and advanced practice, and
in her Doctoral thesis sought to improve the early diagnosis of sepsis in people with
cancer. Shelley lectures and teaches widely across the UK and internationally. Her most
recent research studies have been in the fields of empowering the cancer patient at
home through education and technology, the involvement of the patient in research,
follow-up, ITU and the early identification of patients with sepsis. In 2009, Shelley
was appointed to the clinical reference group for the Competition and Cooperation
panel for the NHS. Shelley is also the Chair of the London Chelsea Research Ethics
Committee. Shelley has published widely with her writing concentrating in the main
on the person with cancer who is acutely or critically ill. Over the last 4 -5 years Shelley
has also written and presented work on clinical leadership and nursing’s influence on
cancer and healthcare policy development, nationally and internationally.
Julie Cairns
Julie is a NZRN who trained at Palmerston North Hospital. Julie has
spent most of her professional life working in cancer nursing and
senior management roles in Melbourne, Australia. From 2010 – 2014
Julie returned to New Zealand and worked in Auckland. During
2013 she was employed by the Ministry of Health, Cancer Program,
to develop the Knowledge and Skills Framework for Cancer
Nursing. In 2014 Julie returned to Melbourne to take up the role of
General Manager, Ambulatory Cancer Services at the Olivia Newton
John Cancer Wellness Centre at Austin Health.
8
Contributing Speakers
Henry Chan, Laboratory Haematology Registrar, Auckland
Anne Fraser, Oncology Nurse Practitioner, Blood and Cancer Service, Auckland
Natalie James, National Cancer Lead, Cancer Nurse Coordinator Initiative
Barry Keane, Nurse Director, Central Cancer Network
Douglas Ormrod, Programme Manager, Genesis Oncology Trust
Karyn Sangster, Director of Nursing Cancer, Counties Manukau DHB
Andrew Simpson, National Clinical Director Cancer, Ministry of Health
Richard Sullivan, Oncologist, Auckland DHB / Medical Director, Northern Cancer Network
Heidi Watson, Nurse Specialist, Auckland DHB
Before prescribing VELCADE please review the Minimum Prescribing Information below.
VELCADE® (bortezomib) – Minimum Data Sheet
Indications: untreated multiple myeloma unsuitable for high dose chemotherapy, in combination with melphalan and
prednisone. Multiple myeloma, received at least one prior therapy, have progressive disease. As part of combination
therapy, for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65
years of age with previously untreated multiple myeloma. Dose and method of use: 1.3 mg/m2 may be administered
intravenously at a concentration of 1 mg/mLas a 3-5s bolus injection or subcutaneously at a concentration of 2.5 mg/mL,
see full Data Sheet for dosing schedule; reduce or withhold dose with haematological toxicity or neuropathy. Retreatment
may be considered for patients who had responded to treatment with VELCADE; see full Data Sheet. Contraindications:
hypersensitivity to bortezomib, boron or mannitol. Precautions: DO NOT ADMINISTER INTRATHECALLY, peripheral
neuropathy, hypotension, cardiac disorders, thrombocytopenia, gastrointestinal adverse events, pulmonary disorder,
reversible posterior leukoencephalopathy syndrome, seizures, tumour lysis syndrome, hepatic events, hepatic impairment,
renal impairment, fertility, lactation, driving or operating machinery. Freq. monitor CBC; pregnancy, lactation, children,
see full Data Sheet. Interactions with other drugs: inhibitors or inducers of cytochrome P450 3A4 or 2C19, oral
hypoglycaemics, caution to be used with concomitant medications that may be associated with peripheral neuropathy
(such as amiodarone, anti-virals, isoniazid, nitrofurantion, statins), or with a decrease in blood pressure. Adverse events:
infections, pyrexia, GI, haematological disturbances, peripheral neuropathy, hypotension, haematoma, headache,
decreased appetite, general psychiatric disorders, dyspnoea, rash, blurred vision, vertigo, myalgia; fatigue, pyrexia, tumour
lysis syndrome (uncommon), pulmonary disorders, others, see full Data Sheet. Presentation: VELCADE is a Prescription
Medicine containing bortezomib 1mg or 3.5 mg per single dose vial. Date of Preparation: 18 December 2012.
Please review approved Data Sheet before prescribing, available at www.medsafe.govt.nz or on
request from Janssen New Zealand, PO Box 62185, Sylvia Park, Auckland, New Zealand. VELCADE
is fully funded, Special Authority criteria apply. NZ-VEL0037 TAPSCH4224 December 2014
9
DON’T MISS
THE NZNO
ONCOLOGY AND
HAEMATOLOGY
CONFERENCE
BREAKFAST
SYMPOSIUM
Saturday, March 21
7.30 am
Management of patients with
Myelodysplastic Syndromes
(MDS) with Vidaza
A practical session on how to best help your MDS
patients with their Vidaza (azacitidine) treatment.
Peter Shuttleworth, Haematology Nurse Coordinator,
Austin Health, Victoria, Australia
Venue: Ko Awatea, Middlemore Hospital Campus
Agenda
6.45 am
Complimentary bus pick up from Holiday Inn,
Auckland Airport
7.00 am – 7.30 am
Breakfast provided (sponsored by Celgene)
7.30 am – 8.30 am
Educational session
Peter Shuttleworth
Peter has developed a vast experience in
haematology and bone marrow transplant
nursing since his career commenced over 20
years ago. He started his nursing career within
the Haem/Onc/BMT unit at the Royal Children’s
Hospital in Melbourne in 1993, before moving up
the road to the Royal Melbourne Hospital (RMH)
in 1996. In 1999 he became the haematology/
BMT Clinical Trials Nurse at RMH, and was
involved in co-ordinating a number of studies
in myeloma during the exciting introduction
of immunomodulators and proteasome
inhibitors. During this time, he was also involved
in the phase III randomised trial of azacitidine in
MDS and low blast count AML.
2010 saw an exciting change in direction,
with Peter’ taking on the role of Haematology
Clinical Nurse Consultant at the Austin Hospital,
Melbourne. The Austin’s unit and it’s trial
capacity was rapidly expanding at the time,
and consequently Peter was responsible for
co-ordinating the azacitidine patients with ALLG
study involvement, as well as those patients
managed within reimbursed indications. The
majority of his time is spent co-ordinating and
managing the outpatient and day oncology
population across the range of haematology
indications.
In accordance with the Code of Practice - Medicines New Zealand, any costs (for example travel or meals) incurred by a partner/spouse, guests, or a family
member travelling with a healthcare professional must not be paid for or subsidised by the company.
Celgene Pty Ltd ABN 42 118 998 771. Level 7, 607 St Kilda Rd, Melbourne VIC 3004, Australia. ZCLG02005
10
11
Registration desk open
Venue: Foyer, Ko Awatea
Plenary 1
Mihi whakatau
Whitiora Cooper
Opening address
Karyn Sangster
‘MIDDLE EARTH’ - visibility and effectiveness of autonomous nursing roles
Julie Cairns
Nursing roles and innovation
Shelley Dolan
8.00am
8.30am - 10.30am
8.30am - 8.45am
8.45am - 9.00am
9.00am - 9.45am
9.45am - 10.30am
FRIDAY PROGRAMME
10.30am - 11.00am Morning tea and exhibition Venue: Rooms 103 and 106
Venue: Lecture Theatre
Chair: Angela Knox
Buses depart Holiday Inn Auckland Airport for Ko Awatea, Middlemore Hospital
7.45am
FRIDAY 20 MARCH 2015
NZNO Cancer Nurses College:
Oncology and Haematology Conference 2015
12
The needs of adolescents/young adults with cancer
Heidi Watson
Chemotherapy dosing in the obese patient
Henry Chan
1.10pm - 1.45pm
1.45pm - 2.20pm
Chair: Anne-Marie Wilkins
Plenary 3
1.10pm - 3.20pm
12.15pm - 1.10pm Lunch and exhibition Venue: Rooms 103 and 106
Day Ward Tour 2
New nurse-led developments for
people with neuroendocrine tumours in
New Zealand
Avril Hull, Ben Lawrence
11.55am - 12.15pm
Evidence on the handling and
administration of biological
agents - an update
Jacky Chan
Is a support group an effective
Day Ward Tour 1
intervention to help address the
specific unmet needs of carers
of people living with or beyond
a haematological malignancy
Amanda Foster
Optimising the patient journey – a
dynamic approach
Nicole Falkner, Larissa Ferguson
11.30am - 11.50am
Concurrent Session 1C
Meet at the ForumPoint2
registration desk 5 minutes
prior to start time
Concurrent Session 1B
Venue: Lecture Theatre 2
Chair: Ella Liang
Implementation of the EviQ Anti-Neoplastic Drug Administration course in the New Zealand setting: An Update
Barry Keane
11.00am - 11.20am
11.30am - 12.15pm Concurrent Session 1A
Chair: Hannah Milner
Plenary 2
11.00am - 11.20am
Chair: Kathryn McWatt
FRIDAY PROGRAMME
13
Afternoon tea and exhibition Venue: Rooms 103 and 106
Plenary 4
ONP - Better care, better health, better outcomes…. or just cheap labour?
Anne Fraser
NZNO’s Visibility of Nursing Campaign
Anne Brinkman
Close of Day 1
Angela Knox
Buses depart Ko Awatea, Middlemore Hospital Campus for Holiday Inn Auckland Airport
NZNO Cancer Nurses College: Oncology and Haematology Conference Dinner
Venue: Jean Batten Ballroom, Holiday Inn Auckland Airport
Theme: Roaring 20’s
3.20pm - 3.50pm
3.50pm - 4.30pm
3.50pm - 4.15pm
4.15 pm - 4.30pm
4.30pm
4.45pm
7.00pm - late
FRIDAY PROGRAMME
Chair: Janene Lawrence
NZNO Cancer Nurses College: Oncology and Haematology Annual General Meeting
2.20pm - 3.20pm
14
Sponsored Breakfast Session Management of patients with Myelodysplastic Syndromes (MDS) with Vidaza
Peter Shuttleworth
Plenary 5
‘Crouch, Touch, Pause and Engage’ - Chemotherapy Redesign Project
Julie Cairns
Quality, safety and an excellent patient experience
Shelley Dolan
7.30am - 8.30am
8.40am - 10.05am
8.40am - 9.20am
9.20am - 10.05am
Chair: Merip T-Ah Sam
The Skills and Knowledge framework for cancer nursing
Angela Knox
10.35am - 11.00am
11.10am - 11.55am Concurrent Session 2A
Chair: Hannah Milner
Plenary 6
10.35am - 11.00am
Chair: Kathryn McWatt
10.05am - 10.35am Morning tea and exhibition Venue: Rooms 103 and 106
Concurrent Session 2C
Meet at the ForumPoint2
registration desk 5 minutes prior to
start time
Registration desk open and breakfast served
7.00am
Chair: Angela Knox
Buses depart Holiday Inn Auckland Airport for Ko Awatea, Middlemore Hospital
6.45am
SATURDAY 21 MARCH 2015
SATURDAY PROGRAMME
15
National perspective of cancer services
Andrew Simpson
Genesis Oncology Trust Clinical Fellowship for Cancer Nurses – where are the applicants?
Douglas Ormrod
Panel discussion:
From your perspective, how are nursing contributions recognised, evaluated and utilised within this
transforming culture?
Andrew Simpson, Richard Sullivan, Julie Cairns, Natalie James
Prize giving
Closing Address
Buses depart Ko Awatea, Middlemore Hospital Campus for Holiday Inn Auckland Airport
12.45pm - 1.05pm
1.05pm - 1.15pm
1.15pm - 1.55pm
1.55pm - 2.05pm
2.05pm - 2.35pm
2.45pm
SATURDAY PROGRAMME
Chair: Cathy Teague
Plenary 7
Venue: Rooms 103 and 106
Day Ward Tour 4
Day Ward Tour 3
12.45pm - 2.35pm
11.55am - 12.45pm Lunch and exhibition
Factors affecting pre-chemotherapy Should a suspicion of cancer
patient education
be disclosed?: A literature
Sarah Ellery
review
Shelley Shea
11.35am - 11.55am
Thrombosis and
Cancer, is it time for
routine pharmaceutical
thromboprophylaxis?
Martyn James, Debi Smith
Collaboration in clinical care
pathway development: Facilitating
timely access to diagnosis and first
treatment for colorectal cancer
Melissa Warren
11.10am - 11.30am
ABSTRACTS
1.
Plenary 1
Friday 20 March 2015 9.00am – 9.45am
“MIDDLE EARTH” - VISIBILITY AND EFFECTIVENESS OF
AUTONOMOUS NURSING ROLES
Julie Cairns
Olivia Newton John Cancer Wellness Centre, Austin Health, Melbourne, Australia
Nursing is traditionally viewed as a “cost”, and the largest one, rather than viewed
as a “revenue”, or value adding opportunity in healthcare. Defining and promoting
nursing practice that directly results in quality patient care outcomes is complex, and
often difficult to separate out from other health care components and influencers.
There is now much discussion about the need to focus attention on how nursing can
contribute to improved patient outcomes and experience, which ultimately reduces
cost and inefficiency in the health system. There is good evidence that quality nursing
can impact on both of these.
In the past few years with massive healthcare reforms afoot, both the US and the
UK have made bold statements in relation to the future of nursing that signal where
governments, the health care industry and the nursing profession need to focus their
attention and resources. These statements include reference to the need for nurses to
work to the full extent of their scope of practice, knowledge and skills which will lead
to an increase in specialist and advanced nursing roles; a recognition that there will be
a blurring of professional boundaries and therefore the need for a stronger (and more
equal) partnership model with medicine and other healthcare professionals to redesign
health systems; and the need for nursing to take a more entrepreneurial stance and
direct and lead care. 1,2
A lot of research has been undertaken in the area of Nurse Sensitive Outcomes, mostly
in the acute setting in the US and a focus on structural variables such as staffing levels.
The identification and validation of Nurse Sensitive Indicators cuts to the core of
professional nursing practice, and will form the basis of the discussion in this address,
- and that is – How does nursing/nursing care make a difference to patient outcomes?
And therefore provide a strong evidence base for nursing to be considered more of a
value added/revenue activity rather than a “cost”.
This keynote will review the issues around the research into the development of Nurse
Sensitive Indicators, and also an overview of a model for the evaluation of effectiveness
of nursing role/s in relation to nurses’ role performance and the impact on patient
outcome and ongoing practice improvement.
References
1. IOM (Institute of Medicine) 2010. The Future of Nursing: Leading Change, Advancing Health.
Washington DC: The National Academies Press
2. Nursing: Towards 2015, Longley, Shaw, Dolan, October 2007, Nursing and Midwifery Council, UK
16
2.
Plenary 1
NURSING ROLES AND INNOVATION
Shelley Dolan
Chief Nurse The Royal Marsden NHS Foundation Trust & Clinical Director, The London
Cancer Alliance.
In 2015 the opportunities for cancer nursing across the world are very exciting.
There is a global refocusing on person-centred care and outcomes coupled with
improved experience. At such a time the door is open for cancer nurse leaders to
seize the opportunity and embrace new roles for innovation always with the care of
the patient and their family at the centre. In its submission to the Prime Ministers
Taskforce in the UK the RCN designed a framework for the evolution of nursing roles.
The framework mandates making quality, safety and innovation the backbone of any
national or international nursing career framework. With a pre-registration and post
registration curriculum that focuses on a person centred and whole systems approach,
coupled with assurance and revalidation of nurses expertise and competence. The
framework then proceeds to focus on clinical nursing leadership, shared systems for
nursing Information Technology to ensure that essential patient information can be
shared across care environments and that patients can be encouraged to use new
technologies in their self -management and monitoring of symptomatology. Finally
the framework focuses on safer nursing skill mix and numbers and on the promotion of
innovation, audit and research to ensure continuous improvement of patient and family
care. As a global cancer community we need to think about the care settings, domain
and populations that we need to serve. It is evident across the better resourced
countries that our cancer population is ageing, will increasingly have cancer and other
comorbidities and will increasingly be wanting to be treated at home or out of hospital
settings. New roles therefore need to span settings and ensure integration of the
experience for the patient. Finally our cancer nursing leaders of the future will need
extended skill sets in leadership across systems, innovation and change practice and
embedding change in a sustainable way.
17
3. Plenary 2
IMPLEMENTATION OF THE EVIQ ANTI- NEOPLASTIC DRUG
ADMINISTRATION COURSE IN THE NEW ZEALAND SETTING: AN
UPDATE
Barry Keane1, Paul Smith2
1
MidCentral Health & Central Cancer Network,
2
Wellington Blood and Cancer Centre & Central Cancer Network
The New Zealand cancer nurses sector has for some time identified the need for an
improved chemotherapy assessment and delivery training programme for nurses
involved in the care of patients receiving chemotherapy. The Australian eviQ online
Anti-neoplastic Drug Therapy Course (ADAC) has been identified as a suitable national
replacement for the New Zealand setting. Based on the Australian experience,
implementation could deliver a consistently well trained cancer nursing workforce more
responsive to patient need both in terms of clinical assessment, treatment delivery
and the ability to provide treatment close to patients’ homes. In partnership with
key stakeholders the National Nurses in Cancer Care Collaborative, which includes
the College of Cancer Nurses, has been working on a plan to introduce the ADAC
programme to New Zealand. In the context of wide interest nationally, the implement
the ADAC is planned for central region firstly, facilitated by the Central Cancer
Network. This paper provides an update on progress with implementing the EviQ Anti
Neoplastic Drug Administration Course (ADAC) in the New Zealand setting, including
a reflection on some of the wider issues influencing cancer nursing development at the
national level.
18
4.
Concurrent Session 1A
OPTIMISING THE PATIENT JOURNEY – A DYNAMIC APPROACH
Nicole Falkner1, Larissa Ferguson 2
1
CNC Upper GI and Liver, Counties Manukau DHB
2
CNC Lung, Counties Manukau DHB
Presentation Summary: Cancer Nurse Coordinator collaboration within Counties
Manukau Health, working towards the common goal of navigating the patient through
the cancer journey. Several initiatives are being developed throughout Counties
Manukau Health cancer services. One of these is a ‘Track and Trigger’ database
developed by the lung tumour stream to assist efficient patient flow, highlight delays
and support the current pilot of rapid access cancer clinics.
19
5. Concurrent Session 1A
Friday 20 March 2015 11.55am – 12.15pm
NEW NURSE-LED DEVELOPMENTS FOR PEOPLE WITH
NEUROENDOCRINE TUMOURS IN NZ
Avril Hull, Ben Lawrence
Auckland District Health Board, Auckland
People with Neuroendocrine Tumours (NETs) face unique challenges that need
individualized patient-focused solutions. NET is an umbrella term for a group of
uncommon cancers that arise from neuroendocrine cells found throughout the body.
NETs range from very slow to very fast growing, and sometimes secrete hormones
that cause debilitating symptoms; making them a challenging group of cancers to
treat. Based on worldwide statistics there might be 250 new NZ patients diagnosed
each year. Fourteen months ago I established my role as a Nurse Specialist (CNS)
for people with NETs under the care of Auckland’s oncology department. Despite a
strong oncology background, I faced a steep learning curve, albeit both enlightening
and humbling. As the only NET CNS in NZ, my experience has mirrored colleagues in
the UK who describe a sense of isolation sometimes felt by both patients and nursing
staff, the limitations of treatment options, and frustration at the lack of educational
resources. My early focus was to develop a NZ-orientated patient information booklet
on NETs. Awareness of NETs in NZ can be further developed by a new patient
organisation called Unicorn Foundation NZ, and I support patients through this group
by attending meetings that highlight the difficulties patients face. I have strong ties
with The NETwork! Research project and the world-leading genomic research on
NETs at the University of Auckland, and assist patents to participate in the project and
help with sample collection. Currently there are no NZ based statistics, so I contribute
to a national NET registry to ascertain NET incidence and prevalence in NZ. To
improve clinical outcomes, I attend a new weekly NET MDM meeting where doctors
present questions about patient care, and I will aim to ensure that the patient voice is
represented. The sub-group of patients with slow growing disease has considerable
potential to benefit from a long-term nurse led clinical care, including management
of secretory symptoms and injection of drugs like octreotide for symptom control,
and better continuity in care. At present I am establishing a weekly nurse-led clinic
for patients with NETs in Auckland. Although this family of tumours are complex and
rare, knowledge and support for this group of patients is developing rapidly in NZ,
and oncology nurses can play a key role in improving the quality and experience of the
patient journey.
20
6. Concurrent Session 1B
IS A SUPPORT GROUP AN EFFECTIVE INTERVENTION TO HELP
ADDRESS THE SPECIFIC UNMET NEEDS OF CARERS OF PEOPLE
LIVING WITH OR BEYOND A HAEMATOLOGICAL MALIGNANCY?
Amanda Foster
Support Services Coordinator, Leukaemia & Blood Cancer New Zealand
Purpose:
The term ‘carer’ is used broadly to describe someone offering unpaid support to a
friend or family member and ‘care’ will vary depending on the individual needs of the
patient which will change in accordance with their disease process.
Extensive literature demonstrates that carers of cancer patients may experience high
levels of depression, anxiety and stress and have poor overall wellbeing. In some cases
carers have more unmet psychosocial needs than the patient.
Research has shown that a support group can be an effective intervention for carers
in a general oncology or palliative care setting. There is currently little evidence
specifically identifying the needs of carers in a haematology setting or recommending
interventions.
Leukaemia & Blood Cancer New Zealand (LBC) is a national non-government
organisation dedicated to supporting families affected by a blood cancer diagnosis
and so is ideally placed to offer support for carers. The aim of this proposal is to pilot a
support group for the carers of haematology patients and to assess the effectiveness of
the intervention in helping to manage unmet needs.
Methods:
A support group specifically for carers of people living with or beyond a blood
cancer diagnosis will be held at the LBC Midland Office. The group will be facilitated
by an LBC Support Services Coordinator and a counsellor specialising in stress
management and relationship counselling. Participants will be asked to complete a self
administrated questionnaire at the completion of the support group.
Results:
It is expected that the results of this pilot will corroborate with similar research in the
general oncology and palliative care setting, which show that support groups are an
effective way to help manage informational and emotional support needs. They help
relieve sense of isolation, reduce stress and anxiety levels and provide a platform for
problem sharing and solving.
21
7.
Friday 20 March 2015 11.55am – 12.15pm
EVIDENCE ON THE HANDLING AND ADMINISTRATION OF
BIOLOGICAL AGENTS – AN UPDATE
Jacky Chan
Pharmacy Department, Middlemore Hospital
Occupational health and safety exposure risks associated with cytotoxic medications
are well established. However, there is little information regarding such risks with
monoclonal antibodies (MABs). Traditionally, many institutions have treated MABs
much like cytotoxic medications with similar pre-cautions and procedures. However,
there are increasing variability to what different hospitals do in the preparation of
MABs. We will review the risks to healthcare personnel associated with the handling
and administration of biological agents, and the updated evidence of how and where a
MAB should be prepared.
22
8. Plenary 3
Friday 20 March 2015 1.10pm – 1.45pm
THE NEEDS OF ADOLESCENT/YOUNG ADULTS WITH CANCER
Heidi Watson
AYA’s present with a unique set of challenges for health professionals. They have
distinct physical, psychological and developmental needs that are significantly different
from those of children and adults. Their developmental needs can and often do
compete with the demands of health care, with issues such as adherence becoming
more of an issue during this time. There is recognition that existing structures and
approaches to care are often not set up to deal with this population suitably.
This potentially may have contributed to the relatively poor AYA cancer improvements
in survival rates over the last 30 years in comparison to children. Current survival rates
for AYA’s with cancer in New Zealand are below international comparisons. There is also
a significant gap that exists in the survival of Maori/Pacific AYA’s in comparison to Non
Maori/Pacific. (Ballantine K, Sullivan M. Adolescent and Young Adult Cancer Incidence
and Survival in NZ 2000 to 2009: Child Cancer Network; 2013)
To maximise health and psychosocial outcomes AYA’s require a complex range of
services that have the ability to work across traditional health service boundaries
and are delivered through a number of disciplines and professional groups. This
presentation will deliver an overview of the needs of AYA cancer patients and the
development of AYA cancer services in NZ.
23
9. Plenary 3
CHEMOTHERAPY DOSING IN THE OBESE PATIENT
Henry Chan
Laboratory Haematology Registrar, Auckland
The prevalence of obesity is increasing in New Zealand and around the world. Other
than the common medical conditions that people often associate with obesity,
increased body mass index has also been linked to various malignancies. Although the
exact linkage and mechanism in how obesity would trigger clonal proliferation remain
uncertain at present, there is little doubt that the healthcare system will face more
obese patients with malignancy as the general population continue to become more
overweight.
Dosing chemotherapy for obese patients can be contentious, as there are often fear
concerning the toxicity of treatment when full uncapped doses are given at high
quantity. Various dose reduction regimens are currently in use, but the scientific
rationale behind some of these approaches is limited. To address this issue, the
American Society of Clinical Oncology has recently performed a comprehensive review
of the data, and they concluded that dose reduction should not be used when dosing
chemotherapy for obese patients with malignancy, especially if the treatment aim is
cure.
The experience from the Department of Haematology in Middlemore Hospital
supports this ASCO recommendation, as it has found no increased in toxicity amongst
the obese patients who received full uncapped doses of R-CHOP chemotherapy.
Importantly, while historical data show that obese patients do worse than normalweight patients, their result shows that both group have comparable survival outcomes.
This finding has been supported by other recent publications, and it is postulated
that the historically poor outcome amongst obese patients may have been due to the
relative underdosing of chemotherapy resulted dose reduction regimens.
24
10. Plenary 4
ONP - BETTER CARE, BETTER HEALTH, BETTER OUTCOMES….
OR JUST CHEAP LABOUR?
Anne Fraser
Oncology Nurse Practitioner, Blood and Cancer Service, Auckland
Medical oncology is a core service underpinning successful treatment of cancer.
As a modality of cancer care, it is facing significant challenges that threaten the
sustainability of cancer care services in New Zealand. As a result of this growth in
demand as well as changes in treatment practices, and expanded treatment options
over the past ten years, current service provision is substantially stretched. This growth
in demand, coupled with the existing constraints on the workforce, facilities and
funding, severely compromises the sustainability of services in the future.
The key challenges that underpin the need for services improvement are:
• Overburdened and limited resources shortages
• A significant projected increase in demand over the next 15 years, driven by
the aging population, higher rates of survival, prolonged treatment times and
expanding treatment options
• Rising patient expectations
Ministry of Health commissioned report, New Models of Care for Medical Oncology
(Cranleigh Health, unpublished) recommended:
Implementing a role delineation framework that identifies the tasks and functions
on the patient care pathway that staff other than senior medical officers ( SMOs) can
provide. This component would include taking on specialist nurses and introduce
options for alternative medical staff in hospitals and communities to focus the capacity
of medical oncologists at key care delivery points.
Nurse practitioners are expert nurses who work within a specific area of practice
incorporating advanced knowledge and skills. They practice both independently
and in collaboration with other health care professionals to promote health, prevent
disease and to diagnose, assess and manage people’s health needs. They provide
a wide range of assessment and treatment interventions, including differential
diagnoses, ordering, conducting and interpreting diagnostic and laboratory tests,
and administrating therapies for the management of potential or actual health needs.
They work in partnership with individuals, families, whanau and communities across a
range of settings. Nurse practitioners prescribe medicines within their specific area of
practice. Nurse practitioners also demonstrate leadership as consultants, educators,
managers and researchers. and actively participate in professional activities, and in
local and national policy development.
This session will explore some of the challenges and practical implications around
registering as an ONP in the NZ setting in the post Cranleigh setting.
25
11.
Plenary 4
NZNO’S VISIBILITY OF NURSING CAMPAIGN
Anne Brinkman
NZNO
At the 2014 NZNO AGM conference members identified two issues on which action is
needed around NZ nursing’s image:
• Publicly promote the value of nursing and nurses, and
• Elevate the professional association profile of NZNO.
The primary purpose of the Visibility in Nursing campaign is to reinforce professional
pride, promote nursing, raising its profile and image publicly. In addressing this goal,
a secondary benefit will be that the professional association profile of NZNO will be
lifted accordingly.
The campaign outcomes include:
• Conveying pride in nursing
• Projecting professionalism
• Empowering members to articulate the value of
nursing
• Demonstrating value of nursing
• Nurses as knowledgeable, skilled health
professionals
• Improving engagement at all levels
26
12. Plenary 5
Saturday 21 March 2015 8.40am – 9.20am
“CROUCH, TOUCH, PAUSE, ENGAGE” – CHEMOTHERAPY
REDESIGN PROJECT
Julie Cairns
Olivia Newton John Cancer Wellness Centre, Austin Health, Melbourne, Australia
Introduction
In 2013 the Victorian Chemotherapy Services Redesign Project was undertaken
to improve the patient’s experience of the Chemotherapy Day Unit/s (CDUs). The
objective of the project was to increase the capability of Victorian CDU management
teams to employ lean business improvement techniques and consistent performance
measures to support locally lead service improvement; to develop a CDU redesign
toolkit and suite of performance measures; and to improve efficiency of participating
CDU’s and share learnings.
Context
In April 2014, the Day Oncology centre at the Olivia Newton John Cancer Wellness
Centre initiated a Chemotherapy Redesign project. The centre was witnessing an
increasing number of patients and treatments, increasing complexity, increasing
numbers of patients being recruited onto clinical trials, and an increase in the length of
time of treatments resulting in a variation of access to treatment times. 56% of patient
experienced a delay of >15mins from their appointment time to their treatment time.
Chair utilisation rate was 65% against best practice of 80%.
Aims/Objectives
The overall aim was to improve the patient experience by reducing waiting times on
the day of treatment. The key objectives were to reduce variation in waiting times, and
to develop a suite of performance measures that could be used to support leaders and
staff to effectively monitor and improve the service.
Methodology
Lean methodology was employed to undertake diagnostics to understand the patient
experience and the different patient, service, and product flows. Data was collected
around waiting times and the pathology collection process. IT scheduling systems were
reviewed and activity, scheduling, and delay data was collected and analysed.
Results
Chair utilisation has increased from 65%, and is now consistently sitting at around 90%.
80% of patients receive their treatment within 15 mins of their scheduled appointment.
A fast track process and area was implemented, chemotherapy regimen times were
reviewed for the scheduler, and the pre chemotherapy patient education process
redesigned.
27
13. Plenary 5
QUALITY, SAFETY AND AN EXCELLENT PATIENT EXPERIENCE
Shelley Dolan
Chief Nurse The Royal Marsden NHS Foundation Trust & Clinical Director, The London
Cancer Alliance
Across the World there is a renewed concentration on refreshing and improving the
quality and safety of healthcare. As we work together globally we have learnt more
about designing processes and care that improve the quality and experience of care
for people with cancer. In the UK The Point of Care Foundation and in the US The
Magnet Hospitals Association has highlighted the need to remember that good staff
engagement and care is an absolute prerequisite for excellent patient care. During the
presentation the evidence from Schwartz rounds will be explored. Originating from the
US a doctor with lung cancer reflected on the need in acute cancer care to make the
unbearable bearable through small acts of kindness. The use of Schwartz rounds has
resulted in a shared experience for staff, improved empathy , and staff having time to
refresh their energy and think about what really matters in care.
If acute cancer care is really to improve the engagement, empowerment and
leadership of front line staff is pivotal. The presentation will include a ward
accreditation system that has been designed by frontline nurses to ensure a holistic
approach to the real time evaluation of care across the whole of the Royal Marsden.
This real worked case is presented as one example of the work that is being led by
clinical cancer nurses across the world to improve outcomes, quality and safety in
acute cancer care. Finally the presentation focuses on the work that cancer nurses
are collaborating on globally to influence and improve the experience of people with
cancer as they are diagnosed and treated. Nurses in the UK and US have collaborated
on using tools such as the Concerns Thermometer as part of a Holistic Needs
Assessment to ensure that cancer care is really patient centred.
28
14. Plenary 6
THE SKILLS AND KNOWLEDGE FRAMEWORK FOR CANCER
NURSING
Angela Knox
Clinical Nurse Manager, Haematology, Middlemore Hospital
Chair NZNO Cancer Nurses College
In collaboration with the Ministry of Health (MoH), the New Zealand Nurses
Organisation (NZNO) Cancer Nurses College (CNC) and the Knowledge and skills
framework reference group, the Skills and Knowledge framework for cancer nursing
(KSFCN) has been completed.
Following a national consultation process, the final draft of the KSFCN was rigorously
reviewed and subsequently approved and endorsed for implementation by the
National Nursing Consortium in November 2014.
Cancer is the leading cause of death in New Zealand and as such requires the nurse to
have the necessary education and tools to enable them to care for people with cancer
across the health continuum in a number of settings. The KSFCN was developed with
MoH support by cancer nurses for cancer nurses.
The KSFCN is intended to complement your current professional development
framework(s) as a tool to assist nurses working across the cancer care continuum
to identify the specific knowledge and skills required to support their personal and
professional development as generalist nurses caring for people with cancer and/or
nurses who wish to specialise in cancer nursing.
This presentation will provide an over view of the importance of the SKFCN for cancer
nurses, with the purpose of encouraging you to utilise the framework in your practice
area.
29
COLLABORATION IN CLINICAL CARE PATHWAY DEVELOPMENT:
FACILITATING TIMELY ACCESS TO DIAGNOSIS AND FIRST
TREATMENT FOR COLORECTAL CANCER
Melissa Warren
Clinical Nurse Specialist – Cancer Care Coordination: Colorectal Cancer
Capital and Coast District Health Board, Wellington
Purpose
The Clinical Nurse Specialist – Cancer Nurse Coordinator (CNC) is a new and evolving
role in New Zealand. The main function of the CNC is to improve patient experience
and outcomes by coordinating care and facilitating a timely diagnosis and initiation of
treatment. Nationally there are 56 CNC’s, with the vast majority having a direct patient
contact care coordination focus. A small number of CNC’s nationwide have been
given a tumour specific pathway development project mandate by their District Health
Boards.
Methods
A clinical project was undertaken to view the current process from initial referral to first
treatment and beyond within the colorectal cancer service at Capital and Coast DHB.
Retrospective process mapping of 15 patients (random sample) diagnosed and treated
for colorectal cancer was carried out by a CNC, which identified potential areas where
improvements may be made to improve patient experience, reduce inequalities and
achieve efficiencies.
Results
Process mapping has proved a valuable tool in making all the steps within the
colorectal cancer pathway visible; engaging MDT members in understanding the
journey from beginning to end and owning any service problems that have emerged.
Process mapping identified a number of areas where there is variability and delays
within the colorectal cancer pathway; referrals, triage prioritisation, cross departmental
systems, lack of pathway and supportive care. This has served as useful starting point
from which to develop clinical care pathways collaboratively with the MDT; from GP
referral to diagnostics and treatment and can be applied by senior cancer nurses
looking to enhance the quality of care across the care continuum in their own cancer
services.
30
FACTORS AFFECTING PRE-CHEMOTHERAPY PATIENT
EDUCATION
Sarah Ellery
Canterbury Regional Cancer and Haematology Service, Oncology Department
Canterbury District Health Board, Christchurch
Purpose:
Over the last 30 years health care and health care related education have evolved
from a basis of paternalism to partnership. In order to understand existing literature
and research on the current approach to pre-chemotherapy patient education an
integrative review was undertaken to explore four questions: What are the factors
affecting pre-chemotherapy patient education? Does evidence or best practice exist
on how pre-chemotherapy should be delivered? What are the most commonly used
methods and resources for delivering pre-chemotherapy patient education? Does
evidence or best practice exist to identify what the content of pre-chemotherapy
patient education should consist of?
Methods:
Integrative literature review
Results:
A number of the key points are summarised:
• People with a cancer diagnosis have individual information needs which require
consideration, and vary over time, throughout the cancer trajectory.
• Assessment of information needs is poorly undertaken or absent. Thorough
assessment is hindered by a number of health system constraints.
• Culture, gender, age, socio-economic status, education, ability to cope and health
literacy levels may influence the information people need, how and when they
receive it, as well as impact on their self-care ability.
• Providing education and information is a dynamic process and should be tailored
to the individual.
• Education is a formal and informal process. Informal opportunities should not be
missed. Reinforcement should occur at each opportunity as it arises.
• Formal education sessions should have a structured approach to delivery with
consistency of content across all staff delivering education.
• Content should be based on evidence and best practice where available.
• Staff training in communication skills and adult learning theory may lead to more
effective education.
• Resource development and environment considerations also exist.
Conclusion:
In conclusion, opportunities exist to improve the pre-chemotherapy education process
for the person with cancer and their family and friends as well as staff involved in the
education process.
31
THROMBOSIS AND CANCER, IS IT TIME FOR ROUTINE
PHARMACEUTICAL THROMBOPROPHYLAXIS?
Martyn James
Thrombosis Nurse Specialist, Counties Manukau DHB
This presentation will examine the evidence around the use of thromboprophylaxis in
cancer patients. Venous thromboembolism (VTE) represents one of the most important
causes of morbidity and mortality in cancer patients. According to population-based
case–control studies, the 2-year cumulative incidence of VTE is between 0.8 and 8%.
The thrombosis unit at Middlemore is dealing with a steadily increasing volume of
patients who have malignancy associated VTE and are working towards strategies to
reduce the incidence of this serious complication.
32
SHOULD A SUSPICION OF CANCER BE DISCLOSED?: A
LITERATURE REVIEW
Shelley Shea
Nelson Marlborough District Health Board, Nelson
A cancer diagnosis can create anxiety for patients and health practitioners alike, so
discussion around a possible cancer diagnosis are often deferred until it has been
confirmed through pathology or high-tech imaging. This reticence may result in
communication difficulties which are unlikely to be helpful to either health practitioners
or patients.
Purpose:
An exploration of the literature seeks to understand whether and how disclosure of a
suspicion of cancer should occur.
Methods:
This literature review is based on the findings of an extensive literature review of
publications pertaining to disclosure of a suspicion of cancer. The PubMed search
engine and the following MESH terms were used: cancer diagnosis or early diagnosis
or cancer suspicion and communication of “breaking bad news” or truth disclosure
and physician-patient relationship. The search was restricted to adults, publications
within 20 years, English language only and not screening, genetics and palliative care.
Citations and reference lists were widely searched.
Results:
There are many opportunities to be had from pre-disclosing a diagnosis and this
review has demonstrated a beginning understanding of the concept. Further research
will enable clarification for clinicians on patient’s experiences whose views are often
discordant with ours. The way a person reacts to a suspected cancer differs between
individuals; this is because it is subjective to the context of the individual person. The
truth should be told, but in a way that doesn’t remove hope, it should be offered rather
than imposed onto patients. Knowledge should be gained of patient’s preferences in
particular to learning difficult news and how that information should be presented. The
truth should be told to individuals as per their wishes instead of assumptions being
made based on what the patient needs to know. Not informing patients of a suspected
cancer can lead to communication breakdowns amongst providers.
33
19. Plenary 7
Saturday 21 March 2015 12.45pm – 1.05pm
NATIONAL PERSPECTIVE OF CANCER SERVICES
Andrew Simpson
National Clinical Director, Cancer, Ministry of Health
The Government has identified high quality health services and healthy communities as
key priorities for health. Within these priorities are specific cancer-related activities that
have a focus on cancer screening, speeding up access to diagnostics and treatment,
improving personalised support to patients and implementing a new cancer health
target.
The Ministry recently released the New Zealand Cancer Plan 2015-18 which sets out
all activities currently underway and planned for the next three years to implement
the Government’s priorities for cancer. The New Zealand Cancer Plan also sets out
a patient pathway framework to guide the focus of the National Cancer Programme
which brings together the work of the Ministry, DHBs and regional cancer networks.
Activities over recent years have focussed on service improvement, mainly through:
• improving coverage and service delivery of cancer screening programmes and
reducing barriers to access implementing a prostate cancer awareness and quality
improvement programme
• implementing the Faster cancer treatment programme through:
• supporting the implementation a National Radiation Oncology Plan that outlines
the linear accelerator and workforce requirements for radiotherapy
• supporting the implementation of a new medical oncology model of care
• establishing an Adolescent and Young Adult clinical network
• supporting an effective National Child Cancer Network
• ensuring that patients with cancer and their families have good psychological and
social support.
The successful implementation of the National Cancer Programme relies on a sector
committed to working together and strong governance structures at national, regional
and local levels. The nursing workforce has played an enormous role in contributing to
the programme through:
• participation on governance and advisory groups at all levels
• work force and quality improvement initiatives eg the Cancer Nurse Coordinator
Initiative, the Cancer Nurse Knowledge and Skills Framework
• clinical leadership roles eg the National Nurse Lead- cancer nurse coordinator
initiative.
34
20. Plenary 7
Saturday 21 March 2015 1.05pm – 1.15pm
GENESIS ONCOLOGY TRUST CLINICAL FELLOWSHIP FOR
CANCER NURSES – WHERE ARE THE APPLICANTS?
Douglas Ormrod
Programme Manager, Genesis Oncology Trust
The Genesis Oncology Trust is an independent registered charity established in 2002
by Genesis Energy as part of the company’s commitment to the community. Genesis
Energy customers donate more the $1 million annually to the Trust, and every $ is
applied to the work of the Trust. To date the Trust has distributed more than $10 million
to aid in the fight against cancer.
The Genesis Oncology Trust funds a broad range of cancer-control research,
training and education, including a Clinical Fellowship for Cancer Nurses which was
established in 2011.
This Fellowship will be awarded to a nurse who is committed to a clinical career with
a major involvement in cancer treatment or care of those affected by cancer. It is
intended for nurses so that they can enhance their practice and expertise through
further clinical training and/or research and thus contribute to improved patient
outcomes in New Zealand. The expectation is that at the end of the Fellowship the
successful applicant will become established in clinical practice in New Zealand. The
duration of the Fellowship is up to two years.
To date interest in the Fellowship has not been overwhelming and only one award
has been made. The purpose of this presentation is to provide information on the
potential application of the award and to solicit feedback to determine if we can
improve the structure of the award to attract more applications.
35
EXHIBITION FLOOR PLAN
2
3
3,594
Room 103
9
90
1
s issued
copied,
ird party
consent
on Ltd.
Angela Harold
Drawn by:
3mtr x .81
Stand Size:
1:49
Scale:
Initial Plan date:
Revised Plan date:
20 May 2014
11 March 2015
Drawing Number:
his drawing is reserved by
3
FP2
Project:
Room/Level:
Venue:
4
Event Co-ordinator:
Maria Fomin
5
6
Show Dates:
NZNOCNCIS 2015
Room 103
Ko Awatea
Room 103
2015
Shell scheme type:
Frontrunner
info@peek.co.nz | www.p
Room 106
3,979
erved by
Client:
8
7
36
Drawn by:
Room 106
Peek Display
Client:
FP2
Event Co-ordinator:
Angela Harold
Show Dates:
2014
Shell scheme type:
Frontrunner
EXHIBITOR DIRECTORY
Aspen Pharmacare
Stand number
9
Celgene2
GSK8
Janssen4
Leukaemia & Blood Cancer New Zealand
5
New Zealand Medical and Scientific Ltd
7
New Zealand Nurses Organisation (NZNO)
Table
Novartis Oncology
1
REM Systems
6
Roche NZ (Ltd)
3
37
EXHIBITOR INFORMATION
ASPEN PHARMACARE
Stand 9
P O Box 62027
Silvia Park
Auckland 1644
T: +64 9 570 1080
F: +64 9 915 9581
E: aspen@aspenpharma.co.nz
www.aspenpharma.co.nz
Product on display:
1. Ferinject®
Aspen Pharmacare offer a diverse range of tried and trusted brands in New Zealand.
The product mix ranges across Ethical, Primary & Secondary care with key brands being
Circadin®, Eltroxin®, Ferinject®, Redipred® and Simdax®. For more information visit
www.aspenpharma.co.nz
CELGENE
Stand 2
PO Box 3035
Wellington 6140
T: 0800 526 529
www.celgene.com
Contact: Kirsty Vercoe
Products on display:
1. Revlimid (lenalidomide)
2. Vidaza (azacitidine)
Celgene is a leading biopharmaceutical company engaged in the discovery,
development and delivery of innovative therapies such as VIDAZA, REVLIMID and
THALOMID which are designed to significantly enhance the quality of life and improve
the prospects for critically ill patients with cancer and other debilitating diseases
worldwide. For further information visit our website www.celgene.com
38
GSK
Stand 8
Private Bag 106600
AUCKLAND 1143
T: +64 9 367 2900
www.gsk.co.nz
Contact: Sean Reeves
1. Votrient
2. Revolade
3. Tyker6
JANSSEN
Stand 4
PO Box 62185
Sylvia Park
AUCKLAND 1644
T: +64 9 588 1300
F: +64 9 588 1398
Contact: Gretchen Hamilton
1. Velcade
2. Zytiga
At Janssen, we collaborate with the world for the health of everyone in it. What matters
most to us is a healthy outcome for each patient. We’re committed to providing safe
and effective medicines as well as the services and support that contribute to healthy
outcomes. One of the fastest growing of the top 10 pharmaceutical companies
globally, we’re focusing our unique model of innovation on some of the most
devastating diseases and the most complex medical challenges of our time, across five
therapeutic areas; Immunology, Oncology, Neuroscience, Cardiovascular Medicine,
and Infectious Disease. Products include Velcade for myeloma and Zytiga for prostate
cancer.
39
LEUKAEMIA & BLOOD CANCER NEW ZEALAND
Stand 5
PO Box 99182
Newmarket
AUCKLAND 1149
T: 0800 151 015
F: +64 9 638 3557
E: supportservices@leukaemia.org.nz
www.leukaemia.org.nz
Contact: Meg Morgan
Leukaemia & Blood Cancer New Zealand (LBC) is the only not-for-profit organisation in
New Zealand dedicated solely to supporting patients and families living with leukaemia
lymphoma, myeloma and blood conditions. In addition LBC supports and funds
research, advocates on behalf of patients, provides information and education and
raises awareness.
NEW ZEALAND MEDICAL AND SCIENTIFIC LTD
Stand 7
PO Box 132400
Sylvia Park
AUCKLAND 1644
T: +64 9 259 4062
F: +64 9 259 4067
E: rhughes@nzms.co.nz
www.nzms.co.nz
Contact: Ruth Hughes
1. Medcomp Power Injectable Ports and PICCS
2. Eusapharma Caphosol mouth rinse
3. Focal Biozorb – 3 dimensional tissue marker
NZMS proudly distributes Medcomp leading edge vascular access devices for the
delivery of chemotherapy via power injectable ports and PICCs. Medcomp, by
continually improving on existing technology can offer a catheter to suit every medical
requirement while also considering you patients comfort.
Caphosol™ for the treatment of Oral Mucositis. A supersaturated solution of calcium
and phosate mouth rinse to assist healing and improve oral health. Commence Cancer
therapy commence Caphosol™.
BioZorb – the 3 dimensional tissue marker used in breast care treatment.
40
NEW ZEALAND NURSES ORGANISATION
Table
T: 021 579 020
www.nzno.org.nz/groups/colleges/cancer_nurses_college
Contact:
Angela Knox, Chair: aknox@middlemore.co.nz
Wendy Jar, Vice-Chair: Wendy.Jar@Cdhb.health.nz
The Cancer Nurses College encompasses a wide ranging group of nurses with an
interest in the care of the person with cancer.
This area may include the disciplines of oncology, haematology, paediatrics, surgery,
community and rural health, research, education, management and health promotion
and palliative care.
NOVARTIS ONCOLOGY
Stand 1
109 Carlton Gore Road
Newmarket
AUCKLAND 1023
T: +64 9 532 8500
F: +64 9 473 1531
E: Hannaki.smalberger@novartis.com
www.novartis.com
Contact: Hannaki Smalberger
Novartis is caring and curing. We are committed to the research, development and
supply of medicines to prevent and cure disease, ease suffering and enhance quality of
life. To find out more about who Novartis is, visit www.novartis.com.
41
REM SYSTEMS
Stand 6
PO Box 90147
Victoria Street West
AUCKLAND 1142
T: +64 9 570 3322
F: +64 9 570 3321
E: bforder@remsystems.co.nz
Contact: Brenda Forder / Lesley Powell
1. CODAN CYTO® Safe preparation and administration of cytostatics
2. CODAN CHEMOPROTECT® Complete protection in the preparation and
administration of cytotoxic drugs
3. EQUASHIELD® 2nd generation closed system transfer devices for hazardous drugs
REM SYSTEMS invites delegates to view our closed systems and protective wear
for administration and compounding of Cytotoxic / Hazardous Medications. REM
SYSTEMS has the CODAN CYTO® Safe Preparation and Administration Systems, which
are used by multiple Oncology and Haematology Units. REM SYSTEMS has recently
launched EQUASHIELD® which is a 2nd Generation Closed System Transfer Device for
Hazardous Medications. EQUASHIELD® Syringes have a unique sealed barrel which
ensures syringe equalisation to prevent the escape of vapors and aerosols. REM
SYSTEMS looks forward to supporting the 2015 conference. ROCHE NZ (LTD)
Stand 3
PO Box 109113
Newmarket
AUCKLAND 1149
T: +64 9 523 9400
F: +64 9 523 9465
E: nz.info@roche.com
www.roche.co.nz
Contact: Paul Schon
1. GAZYVA®
2. MABTHERA®
Roche ranks as the leading oncology pharmaceutical company in the world and is
known internationally for its many innovative contributions to medicine. Globally,
Roche is number one in diagnostics, covering all fields of medical testing.
Roche NZ (Ltd) plays a significant role in improving cancer outcomes for New
Zealanders with a portfolio consisting of the following innovative targeted therapies,
Avastin®, GAZYVA®, Herceptin®, Kadcyla®, MabThera®, Neulastim®, Perjeta®, Tarceva®,
Zelboraf®, and Erivedge®.
In New Zealand, Roche invests heavily in clinical research with almost 38 on going trials
active throughout the country.
42
NOTES
43
NOTES
44
NOTES
45
NOTES
46
NOTES
47
NOTES
48
NOTES
49
NOTES
50
NOTES
51
NOTES
52
NOTES
53
NOTES
54
QUESTIONS FOR SHELLEY DOLAN
55
QUESTIONS FOR SHELLEY DOLAN
KO AWATEA
1
2
3
4
11 12 13 14
107
5
6
7
9
106
10
105
103
102
Exhibition
104
Lecture Theatre 2
101
Technology
help
Rest Rooms
Computer bank
an
k
ute
rb
Co
mp
Reheat area
Water
Station
Wishbone
Café Area
Ground Floor - Korotangi
Exhibition
Emergency
Exit
8
Lecture Theatre 1
Main Entrance
Support Building
Innovation
Centre
Computer
bank
Knowledge Help
Venue Floor Plan
Ground Floor - Korotangi

Oncology & Haematology Conference Handbook

Transcription

Similar documents

Third Annual New Jersey Healthcare Monitor

Foreword - touchONCOLOGY

Treatment Planning: Flexible Options

2015 National CME in Haematology Bombay Hospital Institute of Medical Sciences

OCN Review Course 5.21.2015.doc - Cincinnati Tri

MANAGING LIFE WITH CANCER At Home A MANAGEMENT PLAN FOR YOU

Welcome message from our new president, Piya Shult

JEFF KNIGHT

Bionest Oncology Capabilities 2016

senior radiotherapy medical physicist doha, qatar